focus -WSS

focus

author：hotspot 2025-09-28 23:11:41 - browse：6134

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Having children helps parents live longer, especially after age 80

WSS

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Report cites 'urgent' need to recruit more diverse clinical trial participants

Doctors on social media are being harassed and cyberbullied

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Having children helps parents live longer, especially after age 80

Guardant Health colon cancer test endorsed by FDA advisory panel

explore

focus

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Artificial intelligence use in health care faces greater scrutiny in 2024

23andMe had bad news about my health. I wish a person had delivered it

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Psychedelics group wrestles with new pharma identity

Congress must protect the remaining independent doctors

Heart attack and stroke risk calculators need revising

STAT Boddities: What happens to the brain when we get scared?

Novavax promises a turnaround & Lilly roils the obesity market

Congress considering partial increase for doctor pay in Medicare

hotspot

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Congress considering partial increase for doctor pay in Medicare

U.S. death rates show how politics are affecting public health

Why Eli Lilly’s earnings didn’t quite live up to the hype

Latigo launches with $135 million for Vertex

Beyond aggravation: Constipation is an American epidemic

focus

explore

focus

leisure time